Skip to main content

Converge Bio

Category: AI in Healthcare

A generative AI platform designed to model the 'language of biology' by training large-scale models on DNA, RNA, and protein sequences to accelerate and de-risk drug discovery. Converge Bio was founded in 2024. The company is led by Dov Gertz. Based in Tel Aviv, Israel. Team size: 10-50. Total funding raised: $31M total. Latest round: Series A ($25M, Jan 2026). Key investors include ["Bessemer Venture Partners","TLV Partners","Vintage Investment Partners","Saras Capital"].

Founded
2024
Headquarters
Tel Aviv, Israel
Team size
10-50
Total funding
$31M total

Value proposition

Transitions drug discovery from a slow, trial-and-error laboratory process to a predictive digital design framework, significantly reducing the time and cost required to identify viable therapeutic candidates.

Products and solutions

["Biological Foundation Models (Generative AI for DNA, RNA, and Proteins)","In-silico Sequence Design & Optimization Suite","Predictive Biological Interaction Engine","Custom LLM Training for Proprietary Bio-datasets"]

Unique value

Unlike traditional AI tools that focus on specific protein folding or classification, Converge Bio builds generative 'foundation models' that understand the underlying grammar of all biological sequences, allowing for the creation of entirely novel biological entities.

Target customer

Pharmaceutical companies, biotechnology startups, and academic research institutions involved in drug development and genomic medicine.

Industries served

["Biotechnology","Pharmaceuticals","Genomics","Healthcare AI","Life Sciences"]

Technology advantage

Leverages a cross-disciplinary team with deep expertise in both LLM architecture and CRISPR technology; the platform can simulate biological outcomes at a scale and speed that physical labs cannot match.

How they differentiate

Converge Bio offers a unified generative AI platform that models the 'language of biology' across DNA, RNA, and proteins simultaneously. Unlike competitors that focus on specific protein folding or internal pipelines, Converge provides plug-and-play, explainable AI systems designed to integrate directly into existing pharmaceutical R&D workflows.

Main competitors

["EvolutionaryScale","Generate Biomedicines","Recursion Pharmaceuticals"]

Key partnerships

["Bessemer Venture Partners (Lead Investor)","TLV Partners","The Garage (Early-stage venture lab)","Strategic advisors and investors from Meta, OpenAI, and Wiz"]

Notable customers

["Teva Pharmaceuticals","Compugen","BiomX"]

Major milestones

["Raised $5.5M Seed round led by TLV Partners in Nov 2024","Secured $25M Series A led by Bessemer Venture Partners in Jan 2025","Established strategic partnerships with global pharma leaders like Teva Pharmaceuticals"]

Growth metrics

Grown to a 40-person team; currently running approximately 40 active programs with dozens of pharmaceutical and biotech partners.

Market positioning

AI-as-a-Service (AIaaS) platform provider for the biotechnology and pharmaceutical industries.

Geographic focus

North America (Boston) and Middle East (Tel Aviv, Israel)

Patents and IP

CEO Dov Gertz holds a U.S. patent for a machine-learning method used to discover novel CRISPR systems (developed in collaboration with Nobel laureate Jennifer Doudna).

About Dov Gertz

Dov Gertz is the CEO and Co-Founder of Converge Bio. He previously served as an Entrepreneur In Residence at The Garage and held research and engineering roles at Google. He is a recognized expert in bioinformatics, having developed a machine-learning method for discovering novel CRISPR systems, which resulted in a U.S. patent and a publication co-authored with Nobel laureate Jennifer Doudna.

Official website: